Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosol Amikacin + IV Antibiotics for MDR-GNB VAP
NCT03921645Unknown
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Jan 2018
- Primary completion
- Dec 2019
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of amikacin liposome inhalation suspension in ventilator-associated pneumonia (VAP) (2 arms), sponsored by Shanghai Tenth People's Hospital. Primary endpoints: Clinical Pulmonary Infection Score Changes at 14 days and Renal Function Changes at 14 days. Status: unknown.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT03921645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03921645.